Literature DB >> 26699087

Histidine-rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease.

Matthias Bartneck1, Viktor Fech1, Josef Ehling2, Olivier Govaere3, Klaudia Theresa Warzecha1, Kanishka Hittatiya4, Mihael Vucur1, Jérémie Gautheron1, Tom Luedde1, Christian Trautwein1, Twan Lammers2,5,6, Tania Roskams3, Willi Jahnen-Dechent7, Frank Tacke1.   

Abstract

UNLABELLED: Pathogen- and injury-related danger signals as well as cytokines released by immune cells influence the functional differentiation of macrophages in chronic inflammation. Recently, the liver-derived plasma protein, histidine-rich glycoprotein (HRG), was demonstrated, in mouse tumor models, to mediate the transition of alternatively activated (M2) to proinflammatory (M1) macrophages, which limit tumor growth and metastasis. We hypothesized that liver-derived HRG is a critical endogenous modulator of hepatic macrophage functionality and investigated its implications for liver inflammation and fibrosis by comparing C57BL/6N wild-type (WT) and Hrg(-/-) mice. In homeostatic conditions, hepatic macrophages were overall reduced and preferentially polarized toward the anti-inflammatory M2 subtype in Hrg(-/-) mice. Upon chronic liver damage induced by CCl4 or methionine-choline-deficient (MCD) diet, liver injury and fibrosis were attenuated in Hrg(-/-) , compared to WT, mice. Macrophage populations were reduced and skewed toward M2 polarization in injured livers of Hrg(-/-) mice. Moreover, HRG-deficient mice showed significantly enhanced hepatic vascularization by micro-computed tomography and histology, corroborating proangiogenic activities of M2-polarized liver macrophages. Purified HRG protein induced, but HRG-deficient serum prevented, M1 macrophage differentiation in vitro. Accordingly, Hrg(-/-) mice transplanted with Hrg(+/+) bone marrow, but not Hrg(-/-) -transplanted Hrg(+/+) mice, remained protected from experimental steatohepatitis. Consistent with these findings, patients with chronic hepatitis C and nonalcoholic steatohepatitis significantly up-regulated hepatocytic HRG expression, which was associated with M1 polarization of adjacent macrophages.
CONCLUSIONS: Liver-derived HRG, similar to alarmins, appears to be an endogenous molecular factor promoting polarization of hepatic macrophages toward the M1 phenotype, thereby promoting chronic liver injury and fibrosis progression, but limiting angiogenesis. Therefore, controlling tissue levels of HRG or PGF might be a promising strategy in chronic inflammatory liver diseases.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26699087     DOI: 10.1002/hep.28418

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  31 in total

Review 1.  Liver macrophages in tissue homeostasis and disease.

Authors:  Oliver Krenkel; Frank Tacke
Journal:  Nat Rev Immunol       Date:  2017-03-20       Impact factor: 53.106

Review 2.  Hepatobiliary surgeons meet immunologists: the case of colorectal liver metastases patients.

Authors:  Matteo Donadon; Nina Cortese; Federica Marchesi; Matteo Cimino; Alberto Mantovani; Guido Torzilli
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

3.  Liver-specific loss of Perilipin 2 alleviates diet-induced hepatic steatosis, inflammation, and fibrosis.

Authors:  Charles P Najt; Subramanian Senthivinayagam; Mohammad B Aljazi; Kelly A Fader; Sandra D Olenic; Julienne R L Brock; Todd A Lydic; A Daniel Jones; Barbara P Atshaves
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-03-11       Impact factor: 4.052

4.  Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.

Authors:  Tobias Puengel; Sander Lefere; Jana Hundertmark; Marlene Kohlhepp; Christian Penners; Frederique Van de Velde; Bruno Lapauw; Anne Hoorens; Lindsey Devisscher; Anja Geerts; Stephanie Boehm; Qihong Zhao; John Krupinski; Edgar D Charles; Bradley Zinker; Frank Tacke
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

Review 5.  The role of hypoxia-inducible factors in metabolic diseases.

Authors:  Frank J Gonzalez; Cen Xie; Changtao Jiang
Journal:  Nat Rev Endocrinol       Date:  2018-12       Impact factor: 43.330

6.  Study on Hepatotoxicity of Rhubarb Based on Metabolomics and Network Pharmacology.

Authors:  Shanze Li; Yuming Wang; Chunyan Li; Na Yang; Hongxin Yu; Wenjie Zhou; Siyu Chen; Shenshen Yang; Yubo Li
Journal:  Drug Des Devel Ther       Date:  2021-05-04       Impact factor: 4.162

Review 7.  Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease.

Authors:  Ronan Thibaut; Matthew C Gage; Inès Pineda-Torra; Gwladys Chabrier; Nicolas Venteclef; Fawaz Alzaid
Journal:  FEBS J       Date:  2021-05-02       Impact factor: 5.622

Review 8.  The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Detlef Schuppan; Henning Grønbæk; Konstantin Kazankov; Simon Mark Dahl Jørgensen; Karen Louise Thomsen; Holger Jon Møller; Hendrik Vilstrup; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-03       Impact factor: 46.802

9.  Receptor-interacting protein kinase 3 mediates macrophage/monocyte activation in autoimmune hepatitis and regulates interleukin-6 production.

Authors:  Jun Zhang; Liping Guo; Mengjing Liu; Yang Jing; Simin Zhou; Hongxia Li; Yanni Li; Jingwen Zhao; Xingliang Zhao; Nathasha Karunaratna; Kui Jiang; Lu Zhou; Bangmao Wang
Journal:  United European Gastroenterol J       Date:  2018-01-25       Impact factor: 4.623

10.  Macrophage Activation in Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a Pathway.

Authors:  Guido Carpino; Valerio Nobili; Anastasia Renzi; Cristiano De Stefanis; Laura Stronati; Antonio Franchitto; Anna Alisi; Paolo Onori; Rita De Vito; Gianfranco Alpini; Eugenio Gaudio
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.